Novartis AG (NOVN.VX)
67.45CHF
11:32am EDT
CHF0.15 (+0.22%)
CHF67.30
CHF67.20
CHF67.45
CHF66.60
3,323,170
4,593,856
CHF73.75
CHF52.85
NOVN.VX
About
Overall
| Beta: | 0.79 |
| Market Cap (Mil.): | CHF182,203.91 |
| Shares Outstanding (Mil.): | 2,706.19 |
| Dividend: | 2.30 |
| Yield (%): | 3.42 |
Financials
| NOVN.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.32 | 32.01 | 32.18 |
| EPS (TTM): | 3.67 | -- | -- |
| ROI: | 10.42 | 19.61 | 18.91 |
| ROE: | 14.75 | 20.45 | 19.87 |
US STOCKS-Futures point to flat open before factory data
* Fed's Dudley to speak about national economic conditions
US STOCKS-Futures higher as positive momentum persists
* Fed's Dudley to speak about national economic conditions
US STOCKS-Futures higher as positive momentum persists
NEW YORK, July 2 - U.S. stock index futures rose modestly on Tuesday, indicating positive market momentum would continue as investors remain more comfortable with the economic outlook.
Pfizer, Novartis may join Amgen in bidding for Onyx: sources
NEW YORK - Onyx Pharmaceuticals Inc , whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG , two people familiar with the matter said on Monday.
UPDATE 2-Insmed's lung infection drug fares no better than rival, shares fall
* Drug shows smaller improvement in lung capacity vs rival
Novartis skin drug helps patients with chronic hives
ZURICH - Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study.
Novartis skin drug helps patients with chronic hives
ZURICH, June 26 - Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study.
Novartis tests copy of Amgen's Enbrel in late-stage trial
LONDON - Sandoz, the generics unit of Novartis, has launched a late-stage trial with its biosimilar version of Amgen's Enbrel, consolidating its leading position in developing cheaper copies of complex biotech drugs.
UPDATE 2-AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 bln
* $560 mln upfront payment, further payouts on drug success
Alliance Pharma buys rights to Novartis' obstetric drug Syntometrine
- Specialty pharmaceutical company Alliance Pharma Plc said it bought all existing rights to obstetric drug Syntometrine from Novartis AG for $11.5 million.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
